Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49,633,071
-
Number of holders
-
194
-
Total 13F shares, excl. options
-
36,157,207
-
Shares change
-
-877,573
-
Total reported value, excl. options
-
$3,573,656,170
-
Value change
-
-$112,228,539
-
Put/Call ratio
-
107%
-
Number of buys
-
112
-
Number of sells
-
-74
-
Price
-
$98.85
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2017
236 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2017.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 194 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 36,157,207 shares
of 49,633,071 outstanding shares and own 73% of the company stock.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (4,355,643 shares), Vanguard Group Inc (2,615,069 shares), BlackRock Inc. (2,385,036 shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2,222,500 shares), ORBIMED ADVISORS LLC (2,184,535 shares), PRICE T ROWE ASSOCIATES INC /MD/ (1,976,517 shares), Partner Fund Management, L.P. (1,821,800 shares), FMR LLC (1,708,154 shares), STATE STREET CORP (1,187,559 shares), and D. E. Shaw & Co., Inc. (946,578 shares).
This table shows the top 194 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.